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Intermittent and continuous exposure to 1 ,25(OH)2D3 have
different effects on growth plate chondrocytes in vitro
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Intermittent and continuous exposure to l,25(OH)2D3 have different
effects on growth plate chondrocytes in vitro. Intermittent 1 ,25(OH)2D3
administration is widely used to suppress parathyroid glands in second-
ary (renal) hyperparathyroidism. It is unknown whether the effects of
continuous and intermittent I ,25(OH)D3 differ on vitamin D target
organs other than parathyroids. Using primary cultures of rat chondro-
cytes (tibia) we compared the effects of continuous versus intermittent
exposure to physiologic concentrations of I o,25(OH)2D3 on prolifera-
tion (radiothymidine incorporation), cell count, protein synthesis ([3H]-
leucine incorporation), alkaline phosphatase activity (as a marker of
differentiation) and I a,25(OH)2D3 receptor (VDR) regulation. Cells
were synchronized and then exposed for variable periods to a medium
containing 10% delipidated FCS and iO M to 10—12 M la,25(OH)2D3
(or l/3,25(OH)2D3 as specifity control). Intermittent (8 hr exposure
every 48 hr) as well as continuous (sham washing) administration of
I a,25(OH)2D3 had a biphasic effect on proliferation, that is, stimulation
at low (1012 M) and inhibition at high (108M) concentrations. At l012
M intermittent 1 a,25(OH)2D3 yielded higher cell counts than continuous
l,25(OH)2D3. This was seen in the log phase, which was day 3
(continuous 141 2.3% of solvent control; intermittent 185 2.0%)
and in the plateau phase of growth, which was day 6(128 2.6 vs. 169
2,7% of solvent control). Dependence on extracellular Ca is sug-
gested by the effects of varying nominal Ca concentrations in the
medium and of Ca channel blockers, Even two hours of exposure to
Ia,25(OH)2D3 (1012 54) yielded maximal activation of AP during
postincubation. VDR more than doubled after 24 hours following brief
(8 hr) or continuous exposure to 10 -12 M la,25(OH)2D3 in the absence,
but not in the presence of cycloheximide (5 g/ml). Subsequently VDR
declined with continuous la,25(OH)2D3, but not with intermittent
la,25(OH)2D3. After 48 hours Kd was unchanged, but was
significantly lower with continuous (2807 bound molecules/cell) than
intermittent (5987 molecules/cell) I ,25(OH)2D3, We conclude that
intermittent exposure to I ,25(OH)2D3 in primary chondrocyte cultures
is more effective in (i) stimulating cell proliferation and (ii) sustaining
up-regulated VDR.
It has long been known that in patients with renal failure
secondary hyperparathyroidism can be reversed by administra-
tion of vitamin D U] or its bioactive metabolite la,25(OH)2D3
[21. In an effort to overcome the risk of hypercalcemia, inter-
mittent intravenous administration of la,25(OH)2D3 has been
proposed by Slatopoisky et a! [3]. The efficacy of intermittent
intravenous [3, 4] but also intermittent oral [5—7] 1 ,25(OH)2D3
has been documented by other investigators. It has become
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apparent that even brief exposure of parathyroid cells to
1 ,25(OH)2D3 causes prolonged suppression of the mRNA for
pre-pro-PTH [8, 9] and of circulating intact parathyroid hor-
mone [10, 11]. In head-on comparisons we could show that the
same dose of l,25(OH)2D3 was more efficacious in suppressing
the parathyroids when given intermittently by parenteral bolus
than continuously by osmotic minipump [9].
It has recently become apparent that I a,25(OH)2D3 acts not
only on the classical target organs involved in the homeostasis
of serum calcium but also on other target organs [12]. The
growth cartilage is one well known target of vitamin D [13]. In
view of the potential role of la,25(OH)2D3 in the growth
disturbance of children with renal failure we addressed the
issue whether intermittent versus continuous exposure to
1 ,25(OH)D3 in vitro has different effects on chondrocyte func-
tion.
Methods
Reagents
1 a,25(OH)2-[26,27-methyl-3H]-cholecalciferol (158 Ci/mmol)
was obtained from Amersham Buchler (Braunschweig, Germa-
ny); unlabeled la,25(OH)2D3, 25(OH)D and 1/3,25(OH)2D
were gifts from Dr. Calcanis and Dr. Uskokovic (Hoffmann-La
Roche, Grenzach, Germany); [H]-thymidine (40 Ci/mmol) and
L-[4,5-3H]-leucine (120 to 190 Ci/mmol) were obtained from
New England Nuclear (Dreieich, Germany); F-12 and DMEM
medium, PBS, gentamicin, clostridium collagenase (EC
3.4.24.3), DNAse I (EC 3.1.21.1) and trypan blue were from
Boehringer (Mannheim, Germany). Hydroxyapatite, dithiothre-
Ito!, Triton X-l00 were obtained from Sigma Chemical Co.
(Munich, Germany).
Cell cultures
Epiphyseal chondrocytes obtained from proximal tibial
epiphysis of 60 to 80 g male Sprague-Dawley rats were isolated
and cultured as described [13]. Viability, determined by Trypan
blue exclusion technique, exceeded 90%. For each isolation
procedure pooled growth plates from 5 to 10 animals were used.
Cells were cultured in 35 mm and 100 mm plastic dishes
(Falcon Labware, Oxnard, California, USA) in F-12/DMEM 1/1
medium, supplemented with 25 /.Lg/ml L-ascorbic acid, 10
mmol/liter HEPES, 100 jsg/ml gentamicin, and 10% fetal calf
serum (FCS) or 10% charcoal-stripped (delipidated) FCS (Ch-
FCS) at 37°C, gassed with 95% air/5% CO2. Untreated FCS
contained 1.1 x 10'° M 1,25(OH)2D3. Charcoal stripping was
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Primary chondrocyte cultures
24-Hour serum-free medium
for growth arrest and synchronization
"Pulse treatment" "Continuous treatment"
with 1 ,25(OH)2D3 with 1 ,25(OH)2D3
10% Ch-FCS 10% Ch-FCS
Time interval
as indicated
3 Washings
performed to remove such vitamin D metabolites from FCS. In
appropriate control experiments we excluded that charcoal
treatment of FCS was toxic for chondrocytes [131. Vitamin D
metabolites, dissolved in ethanol to yield a final concentration
of 0.05% ethanol (or ethanol alone as vehicle control) were
added as indicated in the figures.
[3H1-thymidine assay
Incorporation of [3H]-thymidine into DNA was determined in
TCA-precipitate [141. To synchronize cell cycles, cells were
maintained in F-12/DMEM under serum-free conditions for 24
hours. Thereafter, they were grown in fresh medium with 10%
Ch-FCS. Vitamin D metabolites or solvent were added as
indicated. Cultures were then incubated for variable periods of
time up to 48 hours. To remove the vitamin D metabolites prior
to vitamin D free postincubation, the medium was aspirated.
After three washes (fresh medium), medium with 10% Ch-FCS
was added until the cultures were terminated. [3HJ-thymidine (2
pCi) was added for the last four hours. Parallel cultures were
done for cell counting. The protocol is outlined in Figure 1.
To control whether vitamin D metabolites were completely
removed by the washing procedure the following control exper-
iments were performed. [3H]-la,25(OH)2D3 (10—12 M) was
added to the medium supplemented with 10% CH-FCS; the
medium was removed after 10 minutes or eight hours and the
cells washed three times with fresh medium. In the third wash,
0.3 to 0.7% of initially added CPM were detected. The cell layer
was trypsinized and washed three times. The radioactivity in
the cell fraction was 2.7 to 2.9%, corresponding to approxi-
mately 2500 bound molecules 1 ,25(OH)2D3Icell. Binding of
[3H]-1,25(OH)2D to the plastic dishes was not demonstrable.
Chondrocytes were seeded at 100,000 cells per 35 mm dish in
F-12/DMEM medium supplemented with 10% FCS. After 24
hours medium was changed to F-l2/DMEM with 10% Ch-FCS.
Cells were exposed to 10— 12 to 10—8 M of the indicated vitamin
D metabolite (or ethanol). Other than in the radiothymidine
experiments, in this study one series designated "pulse" treat-
ment was exposed to the vitamin D metabolites for eight hours
every other day. Vitamin D metabolites were removed as
described in the assay for [3H]-thymidine incorporation. Sham
washings were done in dishes continuously exposed to
1 ,25(OH)2D3 designated "continuous" treatment as well as in
control dishes. At the end of the experiments cells were
trypsinized and counted using a Neubauer chamber.
[3H]-leucine assay
Cells were grown as described for the [3H]-thimidine assay.
[3H]-leucine (2 tCiI35 mm dish) was added for three hours. The
cell layer was rinsed with cold PBS three times. The cells were
dissolved in NaOH and the radioactivity determined.
Cells were cultured as described for the [3H}-thymidine
assay. Cell cultures were exposed to 1 ,25(OH)2D3 for the times
specified, washed and subsequently postincubated to yield a
total culture time of 24 hours. AP was measured as described
elsewhere [13, 15].
Postincubation Postincubation
in fresh medium with in fresh medium with
10% Ch-FCS 10% Ch-FCS
no 1 ,25(OH)2D3 original 1 ,25(OH)2D3
Measurements Fig. 1. Experimental protocols.
Determination of chondrocyte growth curve
Assay of alkaline phosphatase (AP) activity
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Table 1. Dose response of la,25(OH)2D3 on radiothymidine
incorporation: Biphasic effect
Incorporation o of solvent control
Pulse treatment Continuous
(8 hr) treatment (48 hr)
la,25(OH)2D3 (N = 8) (N = 8)
0 (solvent) 100.0 12.5 100.0 6.5
10—12 M 171.3 9•4b 151.6 35a
10—10 M 146.7 143b 106.3 4.2
10—8 M 84.0 101b 56.9 9.1k
Cell cultures were as described in Methods. Medium was changed to
FCS free medium for 24 hours (synchronization) and then to F-12
medium with 10% Ch-FCS, 1,25(OH)2D3 or solvent (0.05% ethanol)
added. After 8 hours cells were washed three times with fresh medium.
The group with pulsatile treatment was postincubated with 10% Ch-
FCS free• medium without I ,25(OH)2D3, whereas the series with con-
tinuous treatment was re-exposed to the original concentrations of
l,25(OH)2D3. The experiment was terminated after a total culture time
of 48 hours.
P < 0.05 vs. solvent control
b P < 0.01 vs. solvent control by ANOVA
Assay of 1,25(OH)2D3 receptor activity
Whole cell KTED extracts were prepared as described else-
Scatchard analysis
Saturation analysis according to Scatchard [16] was carried
out as described [17]. Fifty microliter aliquots (protein concen-
tration 0.5 to 1.2 mg/ml) were incubated for 16 hours at 4°C with
increasing concentrations of 0.1 to 7.0 flM [3H]-l,25(OH)2D3 in
the absence or presence of 100-fold molar excess of radioinert
1 ,25(OH)2D3. Bound [3H}- 1 .25(OH)2D3 was determined using
the hydroxylapatite assay [181.
Statistics
Data are given as mean SD. Statistical significance was
analyzed on a computed program (Statgraphics, STSC, USA)
using the Mann-Whitney U-test, one way or multifactor
ANOVA as appropriate. P < 0.05 was considered statistically
significant.
Results
Time, hours
Fig. 2. Effect of Ia,25(OH)2D3 on radiothymidine incorporation (time
course). The graph shows [3H]-thymidine incorporation rates (ordinate;
as percent of solvent control) after exposure to la,25(OH)2D3 (10— 12 M)
for the times specified on the abscissa with subsequent postincubation
of variable duration in the absence of 1 a,25(OH)2D3 to yield a total
culture time of 48 hours. Note the significant (P < 0.05) increase of
[3H]-thymidine incorporation over controls for all incubations with
la,25(OH)2D3 exceeding 8 hours. Data are mean SD of 6 parallel
dishes in each group. < 0.05 by ANOVA.
Table 2. Effect of I ,25(OH)2D3 on [3H]-leucine incorporation into
chondrocytes
I a,25(OH)2D3
[log M]
Mode of 1,25(0H)2D3 exposure
Pulse treatment
CPM %
Continuous treatment
CPM %
0 (solvent) 8167 656 100 8167 656 100
102 M 7953 430 97 6811 320 83°
10'° M 6755 767 83° 6107 747 75
10—8 M 6459 583 79 6922 473 84°
Cells were cultured as described in Table 1.
a P < 0.05 vs. solvent control
Radiothymidine and radioleucine incorporation into
synchronized chondrocyte cultures with various temporal
patterns of exposure to I a,25(OH)2D3
As shown in Table 1, 1 a,25(OH)2D3 had a dose-dependent
biphasic effect on radiothymidine incorporation into chondro-
cytes, low concentrations (102 M) increasing and high con-
centrations (10—8 M) decreasing radiothymidine incorporation.
As shown in Figure 2, radiothymidine incorporation into
synchronized chondrocyte cultures was significantly increased
after exposure to l02 M la,25(OH)2D3 for as little as eight
hours and increased significantly with more prolonged expo-
sure. The stimulatory effect tended to wane with exposure for
periods exceeding 12 to 24 hours. This time course was con-
firmed in several independent experiments. The effect was
specific for la,25(OH)2D3 as incubation with 10— 12 M
l/3,25(OH)2D3 for eight hours failed to affect radiothymidine
incorporation.
For up to 48 hours, cell counts of synchronized cultures
exposed to l,25(OH)2D3 did not differ significantly from the
counts at baseline. At this point a modest but significant
inhibition of radioleucine incorporation was seen (Table 2) after
exposure to all but the lowest concentration (in a pulsatile
fashion) of 10— 12 M l,25(OH)2D3.
Varying the ionized Ca concentration in the medium influ-
enced the effect of 1 a,25(OH)2D3 on radiothymidine incorpora-
tion (Table 3). The stimulatory effect was decreased with low as
well as high Ca concentrations. The stimulatory effect of
1,25(OH)2D3 (10_12 M) was partly (by 39%) obliterated by
concomitant incubation with the calcium channel blocker,
verapamil (40 gIml), added five minutes prior to I ,25(OH)2D3
(solvent 2595 448 cpm; 1,25(OH)2D3 4475 566 cpm;
1,25(OH)2D3 + verapamil 3752 480 cpm; P < 0.05). Vera-
pamil alone did not alter baseline radiothymidine incorporation.
0
C00
250
200
150
100
50
0
where [13].
0 4 6 8 12 24 48
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Calcium
concentration
mM
Solvent
1 a,25(OH)2D3
lO12 M
CPM
0.8 3132 272 3661 367k
1.2 2595 448 4475 566a.b
1.5 2400 331 3405 l76
1.8 2416 197 2936 268
Cells were cultured as described in Table 1. The nominal final
concentration of calcium in the medium was achieved by addition of
CaCI2. Data are given as mean SD of 6 parallel dishes per group.
a P < 0.02 l,25(OH)2D3 vs. solvent at given calcium concentrations
(ANOVA)b P < 0.01, 1.2 m Ca vs. 0.8 and 1.5 m, respectively
Cell counts of primary chondrocyte cell cultures (log growth
phase and subconfluent phase)
Effects of various temporal patterns of exposure to
la,25(OH)2D3. As shown in Figure 3, primary chondrocyte
cultures with 10% Ch-FCS that is, delipidated FCS, grew in the
absence of la,25(OH)2D3 to reach a plateau on day 6. Contin-
uous exposure to l0_12 M la,25(OH)2D3 significantly increased
cell counts in the log phase and in the subconfluent phase
without altering the duration of the log phase.
Pulsatile Ia,25(OH)2D3, that is, eight hours every 48 hours,
caused a significant further increase.
Such effect was specific (Figure 4), since stimulation was not
seen with the stereoisomer 1 p,25(OH)2D3. The observations in
Table 1 and Figures 2—4 were confirmed in several independent
experiments.
Time of exposure to la,25(OH)2D3 and induction of alkaline
phosphatase (AP) activity. We examined AP, a specific differ-
entiation marker of chondrocytes and measured the effects of
1 a,25(OH)2D3 on AP activity (Figure 5). As little as a two hour
exposure to 10—12 M la,25(OH)2D3 with subsequent postincu-
bation up to 24 hours in the absence of la,25(OH)2D3 was
sufficient to double the AP activity (corrected for cell number),
irrespective of whether cultures were exposed to 1 ,25(OH)2D3
in a pulsatile or continuous fashion. Subsequently AP activity
showed no further change up to 72 hours (data not shown).
Concomitant administration of 1 a,25(OH)2D3 and cyclohexi-
mide (5 sg/ml) abolished the increase of AP activity.
Maximal specific binding of [3H]-la,25(OH)2D3 by
chondrocyte cultures
Effects of temporal pattern of exposure to lci,25(OH)2D3.
Figure 6 shows specific binding of [3H]-1 ,25(OH)2D3 (vitamin D
receptor VDR) in whole cell extracts of cultured chondrocytes.
Forty-eight hours of exposure to 10- 12 M la,25(OH)2D3 in a
continuous mode failed to modify the slope (Kd) and intercept
(Nmax), while la,25(OH)2D3 in a pulsatile mode caused a
significant increase of Nmax without a change in Kd. The time
course of VDR regulation was explored in the study depicted in
Figure 7. It is obvious that for up to 24 hours the number of
molecules bound per cell more than doubled initially both after
pulsatile (8 hr) and continuous exposure to la,25(OH)2D3 10— 12
M. Such an increase was dependent on protein synthesis, since
cycloheximide (5 /.Lg/ml) added for the last 16 hours of the 24
Time, days
Fig. 3. Effects of pulsatile (top) and Continuous (middle) treatment
with 1,25(OH)2D3 on chondrocyte proliferation (growth curve). Cells
were either exposed to 102 M la,25(OH)2D3 continuously or exposed
to l0_2 M la,25(OH)2D3 for 8 hours every other day. Cells were
washed three times thereafter (sham washings for continuous and
solvent control series). Data are mean SD of 6 parallel dishes per
group): * < 0.01 control (bottom) vs. others; #P < 0.01 pulsatile vs.
continuous.
hour incubation period obliterated the increase of VDR (solvent
control 2840 bound molecules/cell, 1 a,25(OH)2D3 6460,
1 a,25(OH)2D3 with concomitant cycloheximide 3098, respec-
tively, Kd was unchanged). Chondrocytes were vital by trypan
blue exclusion. After 36 hours, however, VDR was drastically
different in chondrocytes exposed to 10—12 M la,25(OH)2D3 in
a continuous as opposed to a pulsatile fashion. Within 36 hours
after incubation with 1 a,25(OH)2D3 VDR had reached baseline
with continuous exposure (compare also Fig. 6). Exposure of
cells to la,25(OH)2D3 might result in spuriously low VDR
measurements by raising the proportion of occupied receptors.
To exclude this artifact, we added iO M la,25(OH)2D3 during
the last hour of the 48 hour incubation. This maneuver failed to
affect Nmax (Ch-FCS control 2,900 molecules/cell; pulse 5,113;
pulse + iO M la,25(OH)2D3 5,447) without altering Kd (data
not given).
Table 3. Effect of I ,25(OH)2D3 on radiothymidine incorporation—
Dependence on extracellular calcium
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Fig. 4. Specificity of the effect of I a,25(OH)2D3 on proliferation of
chondrocytes. Symbols are: (0) control; (ri) pulsatile l/3,25(0H2D3;
() pulsatile la,25(OH)2D3; () continuous la,25(OH)2D3. Protocol is
described in Fig. 3. An additional series of dishes was exposed to
1/3,25(OH)2D3 (l02 M) for 8 hours every other day. No significant
effect of lp,25(OH)2D3 on proliferation was seen, whereas exposure to
lis,25(OH)2D3 in a pulsatile fashion increased cell counts more than the
continuous exposure to the hormone, further confirming the results
shown in Fig. 3. * <0.01 la,25(OH)2D3 vs. solvent control; #P <0.01
la,25(OH)2D3 pulse treatment vs. la,25(OH)2D3 continuous treatment
(ANOVA).
0 5 10 15 20 24
Time, hours
Fig. 5. Induction of alkaline phosphatase activity by Ia,25(OH)2D3Jo 12 M in chondrocytes. A. Comparison of pulsatile or continuous
exposure to I ,25(OH)2D and evaluation of effect of cycloheximide.
Chondrocytes were exposed to 1 ,25(OH)2D3 (l0 12 M) for 8 hours with
subsequent 1 ,25(OH)2D3 free postincubation (pulsatile treatment) or
continued with 1 ,25(OH)2D3 for 24 hours (continuous treatment).
Chondrocyte AP activity was measured after a total incubation time of
24 hours. In a pilot experiment, cycloheximide (5 sg/ml) was shown to
decrease radioleucine incorporation by more than 50%. Cycloheximide
was added 5 minutes prior to 1 ,25(OH)2D3; more than 90% of cyclo-
heximide treated cells were vital by Trypan blue exclusion. AP activity
in cycloheximide treated solvent controls was 55.5 4.4 nmol/105
cells/60 mm vs. 56.4 3.2 nmol/105 cells/60 mm in untreated solvent
controls. Symbols are: *p < 0.01 1,25(OH)2D3 vs. solvent vs.
I ,25(OH)2D3 + cycloheximide; (EJ) controls; () I ,25(OH)2D3;() I ,25(OH)2D3 + cycloheximide. B. Time course. Cells were
exposed to la,25(OH)2D3 l0 12 M for the times indicated on the
abscissa, and then chondrocytes were washed three times. AP activity
was measured immediately (•, without postincubation) or after subse-
quent postincubation in the absence of 1 a,25(OH)2D3 to yield a total
incubation time of 24 hours (with postincubation). *P < 0.03 with
postincubation vs. without postincubation (ANOVA).
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Discussion
The present study clearly shows that the temporal mode of
exposure to 1 ,25(OH)2D3 in primary cultures of rat growth plate
chondrocytes markedly affects DNA synthesis and the rate of
cell proliferation, as evaluated by radiothymidine incorporation
and cell counts, respectively. This was seen both in the log and
in the subconfluent phase of growth. The effect was specific for
la,25(OH)2D3 since the steric analogue 1f3,25(OH)2D3 failed to
influence these parameters. The action of 1 ,25(OH)2D3 on DNA
synthesis was calcium dependent. These effects were paralleled
by a strikingly different effect of pulsatile versus continuous
exposure to 1 ,25(OH)2D3 on 1 ,25(OH)2D3 receptor regulation:
specific binding per cell was higher after pulsatile exposure to
1 ,25(OH)2D3. The latter observation may explain at least in part
the superior efficacy of intermittent exposure to 1 ,25(OH)2D.
These effects in primary chondrocyte cultures parallel the
demonstration that the action of 1 ,25(OH)2D3 on the parathy-
roid gland varies acording to the temporal pattern of adminis-
tration [9]. The present study documents that chondrocytes as
a model of tissue not involved in calcium homeostasis may also
react differently to l,25(OH)2D3, depending on the temporal
pattern of exposure.
It is of note that DNA synthesis (radiothymidine incorpora-
tion) and cell counts, but not chondrocyte differentiation mark-
ers (alkaline phosphatase), were differently affected. This mdi-
cates that only some specific cell functions were sensitive to the
temporal pattern of exposure.
Several methodological points deserve comment. To demon-
strate the effects of 1 ,25(OH)2D3 we synchronized chondro-
cytes by 24 hour culture in a FCS-free artificial medium. This
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would to some extent deplete the cells of 1 ,25(OH)2D3. Out of
concern that low but finite 1 ,25(OH)2D3 (and other vitamin D
metabolites) in FCS may interfere with the results, charcoal-
stripped (delipidated FCS) was used throughout the experi-
ments. Additions of solvent and 1 ,25(OH)2D3 were made to
Ch-FCS. In a previous study [13] we excluded local paracrine
synthesis of 1 ,25(OH)2D3 in our system.
A constant source of concern for in vitro study is whether
cells maintain their phenotypic differentiation. In our primary
cultures chondrocytes retained their polygonal shape as a
marker of differentiated phenotype and ultrastructural analysis
documented maintenance of at least some phenotypic charac-
teristics.
Our findings are in good agreement with results obtained in
other cell systems. We found a biphasic effect of l,25(OH)2D3
on DNA synthesis, that is, stimulation by very low (10— 12M)
and inhibition by higher concentrations (10—8 M), of
Fig. 7. Time course of la,25(OH)2D3 receptor
expression by cultured chondrocytes.
Subconfluent chondrocytes, synchronized(precultured for 24 hr in the absence of FCS
and by implication in the absence of
1 ,25(OH)2D3) were cultured for 8 hours in the
presence of 1,25(OH)2D3 I02 M with
subsequent postincubation up to 48 hours in
the absence of 1 ,25(OH)2D3 (0-0, pulsatile
treatment) or in the presence of 1 ,25(OH)2D3
throughout the experiments (L--L, continuous
treatment). Symbol (•-S) is solvent control.
40 48 Specific binding of [3H]- 1 a,25(OH)2D3
(molecules/cell on the ordinate) is given as a
function of duration of incubation.
1 ,25(OH)2D3. This confirms earlier experiments on cell prolif-
eration and on DNA synthesis [13]. Similar results were found
in human breast cancer cell line T47D [191, fibroblasts [20], and
mouse [21] or human bone cells [22].
The stimulatory effect of low 1 ,25(OH)2D3 on growth carti-
lage is not surprising in view of the fact that in vitamin
D-deficient rickets vitamin D stimulates growth. In systems
using non-delipidated FCS, that is, studying vitamin D-repleted
systems, l,25(OH)2D3 has been shown to inhibit growth at all
concentrations studied [23, 24]. In the study of Harmand et al
[25] on human and rabbit articular chondrocytes, 1 ,25(OH)2D3
left DNA content per flask unchanged at iO' M and decreased
DNA content at lO_12 M and above. As is well known from
mesangial cell cultures, monolayer cultures have growth char-
acteristics which differ completely from those of three-dimen-
sional matrix embedded cultures [26]; therefore these results
are not directly comparable.
A
0.3
0.2
0.1
0123456
B Fig. 6. Specific binding of[3H]-lcs,25(OH)2D3
by cultured chondrocytes. Saturation curve
(A) and Scatchard plot (B). Synchronized
subconfiuent chondrocytes were assayed after
a culture period of 48 hours following
exposure to 102 M la,25(OH)2D3 in a
pulsatile (0, 8 hr) or continuous mode (Lx).
Panel A shows specific binding of [3H]-
1 ,25(OH)2D3 as a function of free [3H]-
1 ,25(OH)2D3. Panel B shows increased
specific binding capacity (intercept on the
abscissa) with pulsatile mode of exposure to
1 ,25(OH)2D3 with no change of affinity
(slope). Nmax solvent control 2847 (•) bound
molecules/cell, continuous treatment 2995,
pulsatile treatment 7106; Kd solvent control
2.7 X 10—10 M, continuous treatment 2.8 x
10—10 M, pulsatile treatment 3.0 x 10b0 M.
Data points represent average of 3 replicate
measurements of pooled material of 4 dishes.
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The effects of 1 ,25(OH)2D3 in our study were dependent on
extracellular Ca, as shown by modification of nominal Ca
concentration in the medium and by the effect of the Ca channel
blocker verapamil. This is again in agreement with previous
findings of MacLaughlin and Chantley Holick [271 and others
[28—30]. It is also well known that l,25(OH)2D3 causes a rapid
transient rise in intracellular calcium [31].
In pilot studies (data not shown) we found that 1 ,25(OH)2D3
did not affect DNA synthesis or cell numbers in cells exposed to
1 ,25(OH)2D3 for less than eight hours. In contrast, exposure of
cells to 1 ,25(OH)2D3 for as little as two hours caused a
progressive increase of AP activity during a 1 ,25(OH)2D3 free
postincubation period. Such increase was dependent on protein
synthesis and was obliterated by coincubation with cyclohex-
imide. The different time course of 1 ,25(OH)2D3 action on cell
differentiation and cell proliferation suggests that different
postreceptor pathways are involved.
The result of increased DNA synthesis in the presence of
diminished radioleucine incorporation is puzzling at first sight.
Several possibilities have to be considered. After 48 hours of
incubation, the number of chondrocytes in synchronized pre-
confluent chondrocyte cultures is not yet different from the
baseline number; the cells are still quiescent. It is possible that
protein synthesis increases later when DNA synthesis is also
stimulated. Reduction of protein synthesis can certainly not be
a steady state phenomenon in view of I ,25(OH)2D3-dependent
increase of chondrocyte cell number (Figs. 3 to 4). Further-
more, the global measurement of radioleucine incorporation
does not differentiate between synthesis of export (matrix)
proteins and synthesis of intracellular proteins, both of which
may be affected differentially by 1 ,25(OH)2D3. Finally, we
cannot exclude influences of 1 ,25(OH)2D3 on cellular uptake of
amino acids and their pool size or binding of radioleucine to
matrix.
As to the mechanism(s) why pulsatile versus continuous
exposure to 1 ,25(OH)2D3 differentially affects the chondrocyte
cell growth, it was sensible to examine the regulation of the
VDR expression. In other endocrine systems receptor regula-
tion is strikingly dependent on the temporal pattern of exposure
to the polypeptide agonist, that is, gonadotropin releasing
hormone and others [32—34]. Our results show that VDR, a
member of the steroid receptor superfamily, is also sensitive to
the temporal pattern of exposure to the agonist (Fig. 7). The
initial increase of specific binding of 1 ,25(OH)2D3 following
exposure to 1 ,25(OH)2D3 described by Chen et al in fibroblasts
[35], and other systems [36], was similar with both pulsatile and
continuous exposure to 1 ,25(OH)2D3. After the initial peak,
however, elevated specific binding capacitiy was maintained
with pulsatile, but decreased with continuous exposure to
1 ,25(OH)2D3. These results are reminiscent of recent findings of
Jacob et al [37] in HL-60 cells. Our binding studies do not
address the issue whether increased binding reflects increased
activity of pre-existing receptor molecules, such as, by phos-
phorylation or interaction with modulating proteins, or reflect
changes in VDR synthesis on the transcriptional level. These
issues are currently under investigation.
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